Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$81.04

0.94 (1.17%)

, ABBV

AbbVie

$69.67

0.91 (1.32%)

07:47
06/12/17
06/12
07:47
06/12/17
07:47

Eli Lilly price target lowered to $90 from $93 at Leerink

Leerink analyst Seamus Fernandez lowered his price target for Eli Lilly (LLY) to $90 to reflect reduced sales forecasts for baricitinib, an oral JAK1/2 inhibitor to treat rheumatoid arthritis which the company collaborates with Incyte (INCY). Following AbbVie's (ABBV) positive Phase 3 data last week for its JAK1 inhibitor upadacitinib, Fernandez dropped his U.S. peak sales estimate for baricitinib by more than 50% to $400M and pushed out his U.S. launch time to 2020 from 2018. The analyst keeps an Outperform rating on Lilly shares.

LLY

Eli Lilly

$81.04

0.94 (1.17%)

ABBV

AbbVie

$69.67

0.91 (1.32%)

INCY

Incyte

$119.04

-0.71 (-0.59%)

  • 13

    Jun

  • 13

    Jun

  • 15

    Jun

  • 15

    Jun

  • 21

    Jun

LLY Eli Lilly
$81.04

0.94 (1.17%)

05/16/17
GSCO
05/16/17
DOWNGRADE
Target $92
GSCO
Buy
Eli Lilly downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Jami Rubin removed Eli Lilly from the Conviction Buy List citing strong year-to-date performance. The analyst maintained a Buy rating and $92 price target citing favorable long-term fundamentals with significant margin expansion.
05/16/17
05/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Sell from Neutral at Citi with analyst Andrew Baum saying his concern over Pfizer's "rising risk to high price" Medicare Part D covered oncology drugs, namely Xtandi, Ibrance and Xalkori, has intensified. He also believes "major transaction risk" for Pfizer remains high. 2. MercadoLibre (MELI) downgraded to Neutral from Overweight at JPMorgan with analyst Andre Baggio citing valuation with the stock up 131% year-over-year. 3. Eli Lilly (LLY) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing strong year-to-date performance. The analyst maintained a Buy rating and $92 price target citing favorable long-term fundamentals with significant margin expansion. 4. Valero (VLO) downgraded to Neutral from Buy at Goldman Sachs with analyst Neil Mehta citing a more balanced risk/reward following the stock's outperformance. 5. NantKwest (NK) downgraded to Sell from Neutral at Citi with analyst Joel Beatty saying the company has a history of "significantly missing" its clinical trial timelines, and this is unlikely to change over the near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/07/17
FBCO
06/07/17
NO CHANGE
Target $38
FBCO
Outperform
ASCO meeting highlights pressure on Pfizer cancer assets, says Credit Suisse
Credit Suisse analyst Vamil Divan said he came away from the ASCO meeting feeling like positive progress by competitors is increasing the pressure on Pfizer's (PFE) cancer assets, specifically pointing to positive data for Roche's (RHHBY) Alecensa, Johnson & Johnson's (JNJ) Zytiga and Eli Lilly's (LLY) abemaciclib. Additionally, competition in the immune-oncology and PARP spaces will make it more challenging for Pfizer to gain traction, added Divan. He keeps an Outperform rating on Pfizer, citing valuation and its dividend yield, but he has concerns about its upcoming patent expirations and growth products.
06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
ABBV AbbVie
$69.67

0.91 (1.32%)

05/25/17
PIPR
05/25/17
NO CHANGE
PIPR
Piper calls AbbVie and Pfizer dividends 'compelling'
In a research note on large-cap Pharma, Piper Jaffray analyst Richard Purkiss calls the dividends of AbbVie (ABBV) and Pfizer (PFE) "compelling." These two dividends "stand out with an unusually compelling combination of high yield alongside a high growth outlook," Purkiss tells investors in a research note, citing his analysis. He reiterates Overweight ratings on both stocks.
05/17/17
MAXM
05/17/17
NO CHANGE
Target $44
MAXM
Buy
Coherus could beat Humira competitors to market by 4 years, says Maxim
Maxim analyst Jason McCarthy said the invalidation of AbbVie's (ABBV) dosing patent for Humira is a "major victory" for Coherus Biosciences (CHRS) that has reduced its risk profile. The last IP hurdle to launching a Humira biosimilar is formulation, where Coherus has the advantage, said McCarthy, who believes the company could be first to market with a biosimilar by late 2018, which would be four years or more ahead of its competition. He raised his price target on Coherus shares to $44 from $43 and keeps a Buy rating on the stock, which is up $1.95, or 8.8%, to $24 in pre-market trading.
05/17/17
SBSH
05/17/17
NO CHANGE
Target $38
SBSH
Buy
Citi sees up to $8/share upside for Coherus on patent win
Citi analyst Mohit Bansal sees $4 to $8 per share upside for Coherus Biosciences (CHRS) after the Patent Trial and Appeal Board ruled in favor of the company's petitions for Inter Partes Review of AbbVie's (ABBV) '135 Patent. The stock in premarket trading is up 9%, or $1.95, to $24.00. The win makes a Humira biosimilar launch from Coherus more realistic, Bansal tells investors in a research note. Further, he believes the news makes an anti-TNF franchise partnership for Coherus with big bio-pharma more likely. He thinks a deal could be announced in the second half of 2017. Bansal keeps a Buy rating on Coherus with a $38 price target.
05/17/17
JEFF
05/17/17
NO CHANGE
Target $90
JEFF
Buy
AbbVie should sell off only 2% today on 'sentiment hit,' says Jefferies
Jefferies analyst Jeffrey Holford believes a "2% sentiment hit" to AbbVie shares is appropriate after the Patent Trial and Appeal Board invalidated the '135 dosing patent for Humira. The stock in premarket trading is down 3%, or $1.85, to $65.00. The analyst, however, does not see the '135 patent as a singular blocking patent against U.S. biosimilars and makes no changes to his estimates. He believes AbbVie's pipeline news flow through the second half of 2017 is being underappreciated and keeps a Buy rating on the shares with a $90 price target.
INCY Incyte
$119.04

-0.71 (-0.59%)

06/06/17
BMOC
06/06/17
NO CHANGE
BMOC
Incyte should be bought on recent weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says that data on the combination of Bristol-Myers' (BMY) Opdivo and Incyte's (INCY) epacadostat "confirmed the benefit" seen in a previous study. The analyst says that the safety of Merck's (MRK) Keytruda in combination with epacadostat is better than the standard of care. He keeps a $166 price target and Outperform rating on Incyte.
06/06/17
FBCO
06/06/17
NO CHANGE
Target $152
FBCO
Outperform
Credit Suisse more confident in Incyte's epacadostat after ASCO
Credit Suisse analyst Alethia Young said the data presented by Incyte at ASCO makes her more confident that epacadostat could play a "major role" in the immuno-oncology landscape. The analyst, who added that there "was a lot of excitement" around the epacadostat data at the meeting, keeps an Outperform rating and $152 price target on Incyte shares.
05/31/17
OPCO
05/31/17
NO CHANGE
Target $135
OPCO
Perform
Incyte price target raised to $135 from $125 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Incyte to $135 saying additional data at ASCO should provide clarity around epacadostat in non-small cell lung cancer. The analyst increased his probability of success for epacadostat plus Keytruda to 48% from 35%, which increases his 2030 risk-adjusted sales estimate to $5.1B from $4.5B. Olson keeps a Perform rating on Incyte.
06/09/17
FBCO
06/09/17
NO CHANGE
FBCO
Outperform
Credit Suisse sees no impact to Incyte's epacadostat from NewLink IDO news
Credit Suisse analyst Alethia Young said she is not surprised that Roche (RHHBY) returned IDO inhibitor GDC-0919 to NewLink (NLNK) after seeing the "disappointing data" at ASCO. She doesn't see an impact to Incyte's (INCY) own IDO inhibitor, epacadostat, from the news, as she thought the data made GDC-0919 appear clinically inferior to epacadostat in combination with PD-1. She keeps an Outperform rating on Incyte shares, adding that investors may get another update on Bristol-Myers' (BMY) internal IDO, BMS-986205, later this year.

TODAY'S FREE FLY STORIES

DDS

Dillard's

$55.18

-0.75 (-1.34%)

15:10
08/17/17
08/17
15:10
08/17/17
15:10
Options
Dillards draws defensive option flow as shares fall »

Dillards draws defensive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
08/17/17
08/17
15:05
08/17/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

EPD

Enterprise Products

$25.07

-0.1 (-0.40%)

15:00
08/17/17
08/17
15:00
08/17/17
15:00
Options
Put buyers in Energy Products Partners »

Put buyers in Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$36.84

-2.11 (-5.42%)

14:58
08/17/17
08/17
14:58
08/17/17
14:58
Recommendations
L Brands analyst commentary  »

L Brands not in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

NUE

Nucor

$54.75

-1.98 (-3.49%)

14:58
08/17/17
08/17
14:58
08/17/17
14:58
Syndicate
Breaking Syndicate news story on Nucor »

Nucor files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.21

0.03 (0.10%)

, TSRO

Tesaro

$112.99

-1.01 (-0.89%)

14:50
08/17/17
08/17
14:50
08/17/17
14:50
Recommendations
AstraZeneca, Tesaro, Clovis analyst commentary  »

Lynparza labeling could…

AZN

AstraZeneca

$29.21

0.03 (0.10%)

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

CLVS

Clovis

$71.77

-0.11 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

GOOG

Alphabet

$926.96

4.74 (0.51%)

, GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

14:50
08/17/17
08/17
14:50
08/17/17
14:50
Periodicals
Google piloting data-friendly Search app in Indonesia, TechCrunch reports »

Google is pilot testing a…

GOOG

Alphabet

$926.96

4.74 (0.51%)

GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

AMAT

Applied Materials

$44.46

0.58 (1.32%)

14:49
08/17/17
08/17
14:49
08/17/17
14:49
Options
Applied Materials options imply 6.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

AZN

AstraZeneca

$29.17

-0.015 (-0.05%)

, CLVS

Clovis

$71.77

-0.11 (-0.15%)

14:44
08/17/17
08/17
14:44
08/17/17
14:44
Hot Stocks
Feuerstein says Lynparza approval shows FDA sees no differences in PARPs »

STAT's Adam…

AZN

AstraZeneca

$29.17

-0.015 (-0.05%)

CLVS

Clovis

$71.77

-0.11 (-0.15%)

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

FSM

Fortuna Silver Mines

$4.49

-0.01 (-0.22%)

14:30
08/17/17
08/17
14:30
08/17/17
14:30
Options
6.5K Fortuna Silver Mines Aug - Sep 4 call spreads for 9c »

6.5K Fortuna Silver Mines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
08/17/17
08/17
14:30
08/17/17
14:30
General news
NY Fed's Survey of Primary Dealers showed expectations for December hike »

NY Fed's Survey of…

PCLN

Priceline

$1,855.72

-5.115 (-0.27%)

14:26
08/17/17
08/17
14:26
08/17/17
14:26
Recommendations
Priceline analyst commentary  »

Priceline recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$12.21

-0.345 (-2.75%)

14:25
08/17/17
08/17
14:25
08/17/17
14:25
Options
Platform Specialty Products call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
08/17/17
08/17
14:25
08/17/17
14:25
General news
Canada CPI Preview »

Canada CPI Preview:…

TLSYY

Telstra

$17.11

0.585 (3.54%)

14:23
08/17/17
08/17
14:23
08/17/17
14:23
Downgrade
Telstra rating change  »

Telstra downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$57.49

-0.785 (-1.35%)

, XLI

Industrial Select Sector SPDR

$67.77

-0.84 (-1.22%)

14:23
08/17/17
08/17
14:23
08/17/17
14:23
Technical Analysis
Technical View: S&P 500 breaks another support layer »

The S&P 500 (SPX) is…

XLK

Technology Select Sector SPDR

$57.49

-0.785 (-1.35%)

XLI

Industrial Select Sector SPDR

$67.77

-0.84 (-1.22%)

XLY

Consumer Discretionary Sector SPDR

$89.23

-0.9 (-1.00%)

XLF

Financial Select Sector

$24.78

-0.26 (-1.04%)

SPY

SPDR S&P 500 ETF Trust

$244.48

-2.465 (-1.00%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

14:18
08/17/17
08/17
14:18
08/17/17
14:18
Hot Stocks
ADP says Pershing presentation contains nothing not already analyzed »

ADP issued a statement in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

$NSD

NASDAQ Market Internals

14:17
08/17/17
08/17
14:17
08/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$30.29

-0.01 (-0.03%)

14:16
08/17/17
08/17
14:16
08/17/17
14:16
Hot Stocks
Goodyear Tire names Christopher Helsel Chief Technology Officer »

The Goodyear Tire &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
08/17/17
08/17
14:16
08/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$52.02

-0.83 (-1.57%)

14:15
08/17/17
08/17
14:15
08/17/17
14:15
Options
US Bancorp put volume heavy and directionally bearish »

Bearish flow noted in US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Oct

  • 17

    Jan

14:10
08/17/17
08/17
14:10
08/17/17
14:10
General news
Fed dove Kashkari said Fed would consider the debt ceiling »

Fed dove Kashkari said…

AVGO

Broadcom

$253.42

-0.27 (-0.11%)

, CSCO

Cisco

$32.34

0.25 (0.78%)

14:08
08/17/17
08/17
14:08
08/17/17
14:08
Hot Stocks
FTC approves final order on Broadcom's acquisition of Brocade »

Following a public…

AVGO

Broadcom

$253.42

-0.27 (-0.11%)

CSCO

Cisco

$32.34

0.25 (0.78%)

BRCD

Brocade

$12.24

0.03 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 06

    Sep

TXMD

TherapeuticsMD

$6.31

0.3718 (6.26%)

14:05
08/17/17
08/17
14:05
08/17/17
14:05
Options
TherapeuticsMD call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

14:02
08/17/17
08/17
14:02
08/17/17
14:02
General news
Trump condemns terror attack in Barcelona, says 'we love you' »

President Trump just…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.